Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Reata Pharma (RETA)

Reata Pharma (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,498,075
  • Shares Outstanding, K 33,228
  • Annual Sales, $ 26,520 K
  • Annual Income, $ -290,170 K
  • 60-Month Beta 2.55
  • Price/Sales 166.37
  • Price/Cash Flow N/A
  • Price/Book 17.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.97
  • Number of Estimates 4
  • High Estimate -1.85
  • Low Estimate -2.02
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -101.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.01 +14.03%
on 03/23/20
208.86 -38.30%
on 03/05/20
-64.07 (-33.21%)
since 03/03/20
3-Month
113.01 +14.03%
on 03/23/20
257.96 -50.05%
on 02/05/20
-72.29 (-35.94%)
since 01/03/20
52-Week
70.00 +84.09%
on 08/28/19
257.96 -50.05%
on 02/05/20
+36.15 (+38.99%)
since 04/03/19

Most Recent Stories

More News
Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations

ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS

RETA : 128.86 (-4.81%)
Reata Pharmaceuticals, Inc. (RETA) Down 37.8% Since Last Earnings Report: Can It Rebound?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RETA : 128.86 (-4.81%)
WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company, is pleased to announce that a patient from the Phase 1 clinical trial of its Berubicin...

RETA : 128.86 (-4.81%)
WBIO.CN : 0.690 (-2.82%)
WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company, is pleased to announce that a patient from the Phase 1 clinical trial of its Berubicin...

RETA : 128.86 (-4.81%)
WBIO.CN : 0.690 (-2.82%)
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December...

RETA : 128.86 (-4.81%)
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 128.86 (-4.81%)
CNS Pharmaceuticals Announces Completion of GMP Manufacturing

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has completed the final...

RETA : 128.86 (-4.81%)
CNSP : 2.16 (+8.00%)
CNS Pharmaceuticals Filed Request with FDA for Pre-IND Meeting for Berubicin

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, filed a Pre-IND meeting request for Berubicin for IV...

RETA : 128.86 (-4.81%)
CNSP : 2.16 (+8.00%)
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of...

RETA : 128.86 (-4.81%)
Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering

Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its...

RETA : 128.86 (-4.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade RETA with:

Business Summary

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address...

See More

Key Turning Points

2nd Resistance Point 142.13
1st Resistance Point 135.49
Last Price 128.86
1st Support Level 124.16
2nd Support Level 119.47

See More

52-Week High 257.96
Fibonacci 61.8% 186.16
Fibonacci 50% 163.98
Fibonacci 38.2% 141.80
Last Price 128.86
52-Week Low 70.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar